Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Abstract PO1-24-04: Gedatolisib, a pan-PI3K/mTOR inhibitor, shows superior potency and efficacy relative to other PI3K/AKT/mTOR pathway inhibitors in breast cancer models

Stefano Rossetti, Aaron Broege, Adrish Sen, Salmaan Khan, Ian MacNeil, Jhomary Molden, Igor Gorbatchevsky, Brian F. Sullivan, Lance Laing

Cancer Res (2024) 84 (9_Supplement): PO1-24-04.

https://doi.org/10.1158/1538-7445.SABCS23-PO1-24-04

Published: 02 May 2024

View articletitled, Abstract PO1-24-04: Gedatolisib, a pan-PI3K/mTOR inhibitor, shows superior potency and efficacy relative to other PI3K/AKT/mTOR pathway inhibitors in breast cancer models

Journal Articles

Abstract 4928: Gedatolisib, a well-tolerated pan-PI3K/mTOR inhibitor, exhibits potent therapeutic effects on endometrial cancer models regardless of their PI3K pathway mutational status

Stefano Rossetti, Aaron Broege, Ian MacNeil, Ben Rich, Jhomary Molden, Brian Sullivan, Lance Laing

Cancer Res (2023) 83 (7_Supplement): 4928.

https://doi.org/10.1158/1538-7445.AM2023-4928

Published: 04 April 2023

View articletitled, Abstract 4928: Gedatolisib, a well-tolerated pan-PI3K/mTOR inhibitor, exhibits potent therapeutic effects on endometrial cancer models regardless of their PI3K pathway mutational status

Journal Articles

Abstract 367: Sub-group of ovarian cancer patients with hyperactive RAS network signaling identified: Dynamic pathway activity test identifies patients that may benefit from PI3K/mTOR or PI3K/mTOR/BCL inhibitors

Stefano Rossetti, Aaron Broege, Joanna Sabat, Shu Wiley, Salmaan Khan, Catherine Kuzmicki, Ian MacNeil, Brian Sullivan, Lance Laing

Cancer Res (2021) 81 (13_Supplement): 367.

https://doi.org/10.1158/1538-7445.AM2021-367

Published: 01 July 2021

View articletitled, Abstract 367: Sub-group of ovarian cancer patients with hyperactive RAS network signaling identified: Dynamic pathway activity test identifies patients that may benefit from PI3K/mTOR or PI3K/mTOR/BCL inhibitors

Journal Articles

Abstract 3198: Hyperactive c-Met and ErbB signaling detected in a sub-group of ovarian patient tumors: Patient sub-group may benefit from c-Met and pan-HER combination therapy

Stefano Rossetti, Catherine Kuzmicki, Aaron Broege, Joanna Sabat, Salmaan Khan, Ian MacNeil, Brian Sullivan, Lance Laing

Cancer Res (2020) 80 (16_Supplement): 3198.

https://doi.org/10.1158/1538-7445.AM2020-3198

Published: 15 August 2020

View articletitled, Abstract 3198: Hyperactive c-Met and ErbB signaling detected in a sub-group of ovarian patient tumors: Patient sub-group may benefit from c-Met and pan-HER combination therapy

Journal Articles

Abstract 4479: Cancer cell ribogenesis: MYC and the integrity of the RNA polymerase I-rRNA machinery

Stefano Rossetti, Andrzej J. Wierzbicki, Nicoletta Sacchi

Cancer Res (2017) 77 (13_Supplement): 4479.

https://doi.org/10.1158/1538-7445.AM2017-4479

Published: 01 July 2017

View articletitled, Abstract 4479: Cancer cell ribogenesis: MYC and the integrity of the RNA polymerase I-rRNA machinery

Journal Articles

Abstract 1401: Deterring breast cancer progression. The critical role of a lipid-sphingolipid epigenetic mechanism of cell fate

Stefano Rossetti, Vincenzo Gagliostro, Nicoletta Sacchi

Cancer Res (2017) 77 (13_Supplement): 1401.

https://doi.org/10.1158/1538-7445.AM2017-1401

Published: 01 July 2017

View articletitled, Abstract 1401: Deterring breast cancer progression. The critical role of a lipid-sphingolipid epigenetic mechanism of cell fate

Journal Articles

Abstract 4532: Deregulation of retinoic acid (RA) epigenetic control of sphingolipid signaling

Stefano Rossetti, Vincenzo Gagliostro, Nicoletta Sacchi

Cancer Res (2016) 76 (14_Supplement): 4532.

https://doi.org/10.1158/1538-7445.AM2016-4532

Published: 15 July 2016

View articletitled, Abstract 4532: Deregulation of retinoic acid (RA) epigenetic control of sphingolipid signaling

Journal Articles

Abstract 180: Expanding the definition of core binding factor leukemia

John A. Fischer, Stefano Rossetti, Arani Datta, Alessandro Beghini, Nicoletta Sacchi

Cancer Res (2015) 75 (15_Supplement): 180.

https://doi.org/10.1158/1538-7445.AM2015-180

Published: 01 August 2015

View articletitled, Abstract 180: Expanding the definition of core binding factor leukemia

Journal Articles

Abstract 4203: Retinoic acid signal and annexins: A vicious circle of breast tumorigenesis

Stefano Rossetti, Wiam Bshara, Johanna Reiners, Francesca Corlazzoli, Austin Miller, Nicoletta Sacchi

Cancer Res (2015) 75 (15_Supplement): 4203.

https://doi.org/10.1158/1538-7445.AM2015-4203

Published: 01 August 2015

View articletitled, Abstract 4203: Retinoic acid signal and annexins: A vicious circle of breast tumorigenesis

Journal Articles

Abstract 2501: Proteomics signature of lack of retinoic acid signal surveillance at early breast cancer stages

Stefano Rossetti, Wiam Bshara, Nicoletta Sacchi

Cancer Res (2014) 74 (19_Supplement): 2501.

https://doi.org/10.1158/1538-7445.AM2014-2501

Published: 01 October 2014

View articletitled, Abstract 2501: Proteomics signature of lack of retinoic acid signal surveillance at early breast cancer stages

Journal Articles

Abstract 3568: Induction of aberrant breast acinar morphogenesis by deregulation of an estrogen receptor alpha circadian circuit.

Stefano Rossetti, Francesca Corlazzoli, Alex Gregorski, Nicoletta Sacchi

Cancer Res (2013) 73 (8_Supplement): 3568.

https://doi.org/10.1158/1538-7445.AM2013-3568

Published: 15 April 2013

View articletitled, Abstract 3568: Induction of aberrant breast acinar morphogenesis by deregulation of an estrogen receptor alpha circadian circuit.

Journal Articles

Abstract 2497: Upregulation of annexin A8 is a common molecular phenotype of aberrant breast acinar morphogenesis induced by different genetic factors.

Stefano Rossetti, Francesca Corlazzoli, Nicoletta Sacchi

Cancer Res (2013) 73 (8_Supplement): 2497.

https://doi.org/10.1158/1538-7445.AM2013-2497

Published: 15 April 2013

View articletitled, Abstract 2497: Upregulation of annexin A8 is a common molecular phenotype of aberrant breast acinar morphogenesis induced by different genetic factors.

Journal Articles

Abstract LB-93: The epigenetic basis of the tumorigenic action of retinoic acid

Stefano Rossetti, MingQiang Ren, Giulia Somenzi, Luigina Tagliavacca, Nicoletta Sacchi

Cancer Res (2010) 70 (8_Supplement): LB-93.

https://doi.org/10.1158/1538-7445.AM10-LB-93

Published: 15 April 2010

View articletitled, Abstract LB-93: The epigenetic basis of the tumorigenic action of retinoic acid

Journal Articles

Abstract #LB-126: MTG16a is a novel repressor of rRNA synthesis, and its nucleolar loss impairs mammary acinar morphogenesis

Stefano Rossetti, Andre Hoogeveen, Nicoletta Sacchi

Cancer Res (2009) 69 (9_Supplement): LB-126.

Published: 01 May 2009

View articletitled, Abstract #LB-126: MTG16a is a novel repressor of rRNA synthesis, and its nucleolar loss impairs mammary acinar morphogenesis

Journal Articles

Disruption of circadian rhythm in breast tumorigenesis

Nicoletta Sacchi, Joseph Esposito, Stefano Rossetti

Cancer Res (2008) 68 (9_Supplement): 5172.

Published: 01 May 2008

View articletitled, Disruption of circadian rhythm in breast tumorigenesis

Journal Articles

Derangement of MTG16, a nucleolar tumor suppressor, leads to aberrant breast acinar morphogenesis

Stefano Rossetti, Andre Hoogeveen, Joseph Esposito, Nicoletta Sacchi

Cancer Res (2007) 67 (9_Supplement): 1254.

Published: 01 May 2007

View articletitled, Derangement of MTG16, a nucleolar tumor suppressor, leads to aberrant breast acinar morphogenesis

Journal Articles

Dietary retinol and retinoic acid promote the growth and invasiveness of breast cancer cells with an aberrant epigenotype

MingQiang Ren, Stefano Rossetti, Nicoletta Sacchi

Cancer Res (2007) 67 (9_Supplement): 1660.

Published: 01 May 2007

View articletitled, Dietary retinol and retinoic acid promote the growth and invasiveness of breast cancer cells with an aberrant epigenotype

Journal Articles

Epigenetic link between RA and TGFB signaling

Stefano Rossetti, Mingqiang Ren, Giulia Somenzi, Nicoletta Sacchi

Cancer Res (2007) 67 (9_Supplement): 5383.

Published: 01 May 2007

View articletitled, Epigenetic link between RA and TGFB signaling

Journal Articles

A Repressive Epigenetic Domino Effect Confers Susceptibility to Breast Epithelial Cell Transformation: Implications for Predicting Breast Cancer Risk

Gaia Bistulfi, Silvia Pozzi, MingQiang Ren, Stefano Rossetti, Nicoletta Sacchi

Cancer Res (2006) 66 (21): 10308–10314.

https://doi.org/10.1158/0008-5472.CAN-06-1052

Published: 01 November 2006

View articletitled, A Repressive Epigenetic Domino Effect Confers Susceptibility to Breast Epithelial Cell Transformation: Implications for Predicting Breast Cancer Risk

Journal Articles

Induction of RARB2 epigenetic silencing in breast cancer cells unexpectedly reveals the tumor promoter face of retinoic acid

Mingqiang Ren, Stefano Rossetti, Giulia Somenzi, Riccardo Ghidoni, Nicoletta Sacchi

Cancer Res (2006) 66 (8_Supplement): 384.

Published: 15 April 2006

View articletitled, Induction of RARB2 epigenetic silencing in breast cancer cells unexpectedly reveals the tumor promoter face of retinoic acid

Update search

NARROW

Format

Journal

Article Type

Issue Section

Date

Availability

Abstract PO1-24-04: Gedatolisib, a pan-PI3K/mTOR inhibitor, shows superior potency and efficacy relative to other PI3K/AKT/mTOR pathway inhibitors in breast cancer models

Abstract 4928: Gedatolisib, a well-tolerated pan-PI3K/mTOR inhibitor, exhibits potent therapeutic effects on endometrial cancer models regardless of their PI3K pathway mutational status

Abstract 367: Sub-group of ovarian cancer patients with hyperactive RAS network signaling identified: Dynamic pathway activity test identifies patients that may benefit from PI3K/mTOR or PI3K/mTOR/BCL inhibitors

Abstract 3198: Hyperactive c-Met and ErbB signaling detected in a sub-group of ovarian patient tumors: Patient sub-group may benefit from c-Met and pan-HER combination therapy

Abstract 4479: Cancer cell ribogenesis: MYC and the integrity of the RNA polymerase I-rRNA machinery

Abstract 1401: Deterring breast cancer progression. The critical role of a lipid-sphingolipid epigenetic mechanism of cell fate

Abstract 4532: Deregulation of retinoic acid (RA) epigenetic control of sphingolipid signaling

Abstract 180: Expanding the definition of core binding factor leukemia

Abstract 4203: Retinoic acid signal and annexins: A vicious circle of breast tumorigenesis

Abstract 2501: Proteomics signature of lack of retinoic acid signal surveillance at early breast cancer stages

Abstract 3568: Induction of aberrant breast acinar morphogenesis by deregulation of an estrogen receptor alpha circadian circuit.

Abstract 2497: Upregulation of annexin A8 is a common molecular phenotype of aberrant breast acinar morphogenesis induced by different genetic factors.

Abstract LB-93: The epigenetic basis of the tumorigenic action of retinoic acid

Abstract #LB-126: MTG16a is a novel repressor of rRNA synthesis, and its nucleolar loss impairs mammary acinar morphogenesis

Disruption of circadian rhythm in breast tumorigenesis

Derangement of MTG16, a nucleolar tumor suppressor, leads to aberrant breast acinar morphogenesis

Dietary retinol and retinoic acid promote the growth and invasiveness of breast cancer cells with an aberrant epigenotype

Epigenetic link between RA and TGFB signaling

A Repressive Epigenetic Domino Effect Confers Susceptibility to Breast Epithelial Cell Transformation: Implications for Predicting Breast Cancer Risk

Induction of RARB2 epigenetic silencing in breast cancer cells unexpectedly reveals the tumor promoter face of retinoic acid

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only